CA3198406A1 - N-acetylgalactosamine(galnac)-derived compounds and oligonucleotides - Google Patents

N-acetylgalactosamine(galnac)-derived compounds and oligonucleotides

Info

Publication number
CA3198406A1
CA3198406A1 CA3198406A CA3198406A CA3198406A1 CA 3198406 A1 CA3198406 A1 CA 3198406A1 CA 3198406 A CA3198406 A CA 3198406A CA 3198406 A CA3198406 A CA 3198406A CA 3198406 A1 CA3198406 A1 CA 3198406A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
optionally substituted
nhac
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3198406A
Other languages
English (en)
French (fr)
Inventor
Zhen Li
Rui ZHU
Mehdi Michel Djamel Numa
Bo Cheng
Chase Robert OLSSON
Chandramouli CHIRUTA
Indrasena Reddy Kummetha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AdaRx Pharmaceuticals Inc
Original Assignee
AdaRx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AdaRx Pharmaceuticals Inc filed Critical AdaRx Pharmaceuticals Inc
Publication of CA3198406A1 publication Critical patent/CA3198406A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3198406A 2020-10-09 2021-10-08 N-acetylgalactosamine(galnac)-derived compounds and oligonucleotides Pending CA3198406A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063089936P 2020-10-09 2020-10-09
US63/089,936 2020-10-09
US202063113801P 2020-11-13 2020-11-13
US63/113,801 2020-11-13
US202063131317P 2020-12-29 2020-12-29
US63/131,317 2020-12-29
US202163141300P 2021-01-25 2021-01-25
US63/141,300 2021-01-25
US202163146276P 2021-02-05 2021-02-05
US63/146,276 2021-02-05
US202163251580P 2021-10-01 2021-10-01
US63/251,580 2021-10-01
PCT/US2021/054318 WO2022076922A1 (en) 2020-10-09 2021-10-08 N-ACETYLGALACTOSAMINE(GAlNAc)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES

Publications (1)

Publication Number Publication Date
CA3198406A1 true CA3198406A1 (en) 2022-04-14

Family

ID=81126164

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3198406A Pending CA3198406A1 (en) 2020-10-09 2021-10-08 N-acetylgalactosamine(galnac)-derived compounds and oligonucleotides

Country Status (10)

Country Link
US (1) US20240083934A1 (https=)
EP (1) EP4225322A4 (https=)
JP (1) JP2023546369A (https=)
KR (1) KR20230113285A (https=)
CN (2) CN121108223A (https=)
AU (1) AU2021359017A1 (https=)
CA (1) CA3198406A1 (https=)
IL (1) IL302000A (https=)
MX (1) MX2023004170A (https=)
WO (1) WO2022076922A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11649260B2 (en) 2021-06-18 2023-05-16 Hongene Biotech Corporation Functionalized N-acetylgalactosamine nucleosides
EP4396193A4 (en) 2021-08-30 2025-07-02 Hongene Biotech Corp FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES
JP2024546585A (ja) 2021-12-15 2024-12-26 ホンジーン バイオテック コーポレイション 官能基化ｎ－アセチルガラクトサミンアナログ
JP2025517196A (ja) * 2022-05-13 2025-06-03 エーダーエックス ファーマシューティカルズ， インコーポレイテッド 合成骨格を有するオリゴヌクレオチド及びその合成
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
CN119019354B (zh) * 2023-05-24 2025-07-22 北京炫景瑞医药科技有限公司 化合物及其制备方法和用途
WO2024240101A1 (zh) * 2023-05-24 2024-11-28 北京炫景瑞医药科技有限公司 GalNAc化合物、缀合物、组合物以及它们的用途
CN119019475B (zh) * 2023-05-24 2026-02-06 北京炫景瑞医药科技有限公司 GalNAc化合物、缀合物、组合物以及它们的用途
WO2025140434A1 (zh) * 2023-12-26 2025-07-03 成都倍特药业股份有限公司 一种肝靶向化合物及其在药物缀合物中的用途
CN121263426A (zh) * 2024-05-09 2026-01-02 石药集团中奇制药技术（石家庄）有限公司 GalNAc衍生物及其寡聚核苷酸缀合物
CN118638166B (zh) 2024-08-15 2024-12-17 北京悦康科创医药科技股份有限公司 含有三氮唑结构的GalNAc化合物及其寡核苷酸缀合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6852485B1 (en) * 2002-01-22 2005-02-08 California State University Fullerton Foundation Method for identifying a compound for the treatment of microorganism infections by inhibiting energy storage and utilization in pathogens
AU2009298802A1 (en) * 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
CN111808084A (zh) * 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
GB201408623D0 (en) * 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
KR20180031025A (ko) * 2015-07-31 2018-03-27 아크투루스 쎄라퓨틱스, 인크. 약물 전달을 위한 다중 리간드 제제
CA3020585A1 (en) * 2016-04-11 2017-10-19 Arbutus Biopharma Corporation Targeted nucleic acid conjugate compositions

Also Published As

Publication number Publication date
EP4225322A4 (en) 2024-12-11
IL302000A (en) 2023-06-01
WO2022076922A1 (en) 2022-04-14
CN121108223A (zh) 2025-12-12
AU2021359017A9 (en) 2024-09-26
CN121108222A (zh) 2025-12-12
MX2023004170A (es) 2023-06-27
KR20230113285A (ko) 2023-07-28
AU2021359017A1 (en) 2023-05-25
JP2023546369A (ja) 2023-11-02
US20240083934A1 (en) 2024-03-14
EP4225322A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
CA3198406A1 (en) N-acetylgalactosamine(galnac)-derived compounds and oligonucleotides
JP7696310B2 (ja) オリゴヌクレオチド組成物およびその方法
JP2023526975A (ja) オリゴヌクレオチド組成物及びその方法
JP2022000023A (ja) オリゴヌクレオチド組成物およびその方法
AU2020263390B2 (en) Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof
JP2023526533A (ja) 二本鎖オリゴヌクレオチド組成物及びそれに関連する方法
JP2022513719A (ja) オリゴヌクレオチド組成物及びその方法
JP6885999B2 (ja) 水溶性プロドラッグ
CN112218664A (zh) 寡核苷酸组合物及其使用方法
CN114206389A (zh) 用于靶向递送治疗剂的多价配体簇
US12109207B2 (en) Methods of using 4(1H)-quinolone derivatives
JP2023535026A (ja) ステープルペプチドおよびその方法
PT98341A (pt) Processo para a preparacao de derivados de purina
EP0607367A1 (en) Novel adenosine derivatives
US20260000775A1 (en) a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF
JP2025507851A (ja) Ｃｂ１リガンドコンジュゲート化合物及びその使用
CN113149978A (zh) 一种中间体化合物、制备方法及其用途
AU2019318046A1 (en) Histone demethylase 5 inhibitors and uses thereof
US9714265B2 (en) Mutagenic nucleoside analogs and uses thereof
CN116546989A (zh) N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸
CN113336816B (zh) 胞苷类化合物及其抗肿瘤用途
US20250312367A1 (en) Oligonucleotides having a synthetic backbone and synthesis thereof
WO2026096688A1 (en) Oligonucleotide compositions and methods thereof
HK40040068A (en) Oligonucleotide compositions and methods of use thereof
CN111170996A (zh) 具有alk抑制活性的嘧啶衍生物及其合成方法和应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241004

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250922

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250922

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251003

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251003

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251124

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251124

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251125